First Trust Capital Management’s European Biotech Acquisition Corp. Units EBACU Stock Holding History

First Trust Capital Management’s Portfolio EBACU Stock Details EBACU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-220,000	Closed	-$2.15M	–	479
2022 Q2	$2.15M	Hold	220,000	–	–	0.15%	168
2022 Q1	$2.17M	Hold	220,000	–	–	0.23%	83
2021 Q4	$304K	Buy	220,000 +10,000	+5%	+$99.1K	0.05%	191
2021 Q3	$2.09M	Hold	210,000	–	–	0.32%	70
2021 Q2	$2.1M	Buy	+210,000	New	+$2.1M	0.31%	62

Other funds holding EBACU

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

MTCM

Mint Tower Capital Management Amsterdam, Netherlands $871M AUM 8.61% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Wealthspring Capital West Harrison, New York $448M AUM 8.38% 1-Year Est. Return

SIA

Schechter Investment Advisors Birmingham, Michigan $1.21B AUM 8.73% 1-Year Est. Return

Walleye Trading New York $87.6B AUM 68.17% 1-Year Est. Return

CSS

Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return

CCA

Castle Creek Arbitrage Avon, Colorado $425M AUM 7.4% 1-Year Est. Return

First Trust Capital Management's EBACU Position: Q3 2022 in Review

First Trust Capital Management sold out of European Biotech Acquisition Corp. Units (EBACU) in Q3 2022, closing a stake of 220,000 shares — an estimated $2.15M sold.

First Trust Capital Management first reported a position in EBACU in Q2 2021 and held it in 5 quarters. The position peaked at $2.17M in Q1 2022. 18 funds tracked by Wall St. Rank hold EBACU as of Q3 2022.

First Trust Capital Management reported no remaining European Biotech Acquisition Corp. Units position as of Q3 2022 after selling out during the quarter.
First Trust Capital Management sold 220,000 European Biotech Acquisition Corp. Units shares in Q3 2022, an estimated $2.15M.
First Trust Capital Management first reported a position in European Biotech Acquisition Corp. Units in Q2 2021 and held it in 5 quarters.
First Trust Capital Management's European Biotech Acquisition Corp. Units position peaked at $2.17M in Q1 2022.
18 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Units as of Q3 2022.

Based on First Trust Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.